The response of diffuse large cell and other intermediate grade non-hodgkin's lvmphomas to adriamvcin containinr combination chemotherapy

Michael Lishner, Joyce Slingerland, Chau Theresa, Simon B. Sutcliffe

Research output: Contribution to journalArticle

Abstract

Adriamycin containing combination chemotherapy (ACCC) is usually delivered to patients with stages III, IV diffuse large cell (DLCL) non-Hodgkin's lymphoma (NHL). Although this mode of therapy is also commonly used in other intermediate grade lymphomas, it's role in the latter subset of patients is not well defined. In a retrospective analysis we evaluated and compared the outcome of previously untreated DLCL and non-DLCL intermediate grade lymphoma patients who received as initial therapy, "first generation" ACCC. No differences in response and relapse rates between these subgroups were observed. The trend towards the survival advantage observed for the non-DLCL patients, is probably due to a lower mortality over 5-8 years, for complete responders.

Original languageEnglish (US)
Pages (from-to)131-136
Number of pages6
JournalLeukemia and Lymphoma
Volume13
Issue number1-2
DOIs
StatePublished - Jan 1 1994
Externally publishedYes

Keywords

  • Combination chemotherapy
  • Diffuse large cell lymphoma adriamycin
  • Intermediate grade lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The response of diffuse large cell and other intermediate grade non-hodgkin's lvmphomas to adriamvcin containinr combination chemotherapy'. Together they form a unique fingerprint.

  • Cite this